Literature DB >> 9096589

Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.

T Ueki1, J Fujimoto, T Suzuki, H Yamamoto, E Okamoto.   

Abstract

The c-met proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), a potent mitogen and motogen for epithelial cells. Because of its profound effects on cell growth and motility, HGF may be important in the development of cancer metastases in hepatocellular carcinoma (HCC). In this study, we examined HGF concentration and expression of the c-met-proto-oncogene product (c-met) in 62 patients with HCC to determine the relationship between the level of expression and clinicopathological features, and patient outcome following hepatectomy. Western blotting was used to examine the c-met expression, and HGF concentration in tumors was measured using an enzyme-linked immunosorbent assay. c-met was found to be overexpressed in HCC compared with nontumorous liver tissue (P < .01), and correlated with an increased incidence of intrahepatic metastases (P = .039). Patients were divided into two groups, low c-met HCC and high c-met HCC. Patients with high c-met HCC had a significantly shorter 5-year survival than patients with low c-met HCC (33.5% vs. 80.3%, respectively; P < .05). However, there was no correlation between HGF concentration in the tumor tissue and clinicopathological factors and patient survival. These results indicate that expression of c-met played an important role in tumor growth and metastases in patients who underwent hepatectomy for HCC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096589     DOI: 10.1002/hep.510250413

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  60 in total

1.  Differentially expressed genes in hepatocellular carcinoma induced by woodchuck hepatitis B virus in mice.

Authors:  X Y Cao; J Liu; Z R Lian; M Clayton; J L Hu; M H Zhu; D M Fan; M Feitelson
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Cloning of differentially expressed genes in human hepatocellular carcinoma and nontumor liver.

Authors:  X Y Cao; J Liu; Z R Lian; M Clayton; J L Hu; M H Zhu; D M Fan; M Feitelson
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.

Authors:  K Murakami; R Sakukawa; T Ikeda; T Matsuura; S Hasumura; S Nagamori; Y Yamada; I Saiki
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma.

Authors:  Xin-Rong Liu; Rou-Li Zhou; Qing-Yun Zhang; Ye Zhang; Yue-Ying Jin; Ming Lin; Jing-An Rui; Da-Xiong Ye
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study.

Authors:  Zhi Li Wang; Ping Liang; Bao Wei Dong; Xiao Ling Yu; De Jiang Yu
Journal:  J Gastrointest Surg       Date:  2007-10-18       Impact factor: 3.452

Review 6.  microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Xiaofei Li; Wenjun Yang; Lianqing Lou; Yongxin Chen; Shuang Wu; Guoqiang Ding
Journal:  Dig Dis Sci       Date:  2014-01-04       Impact factor: 3.199

Review 7.  Emerging signaling pathways in hepatocellular carcinoma.

Authors:  Agrin Moeini; Helena Cornellà; Augusto Villanueva
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 8.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

9.  4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

Authors:  K Murakami; T Matsuura; M Sano; A Hashimoto; K Yonekura; R Sakukawa; Y Yamada; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

10.  Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.

Authors:  Mingchao Wang; Yin Sun; Junjie Xu; Jieyang Lu; Kefeng Wang; Dong-Rong Yang; Guosheng Yang; Gonghui Li; Chawnshang Chang
Journal:  Int J Cancer       Date:  2018-04-02       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.